Eli Lilly and Co. said Monday that it has begun human trials of an antibody treatment for Covid-19.
The Indianapolis-based pharmaceutical company developed the
treatment, called LY-CoV5555, with AbCellera. It is based on antibodies
found in the blood of a recovered Covid-19 patient.
Phase 1 trials are taking place at medical centers including in New
York City and Los Angeles. If the trials show that the treatment is
safe, Eli Lilly plans additional trials both in non-hospitalized
patients and in people who are not sick, to test the medicine’s value as
a preventative.
If the trials are successful, the company said it hopes to have several hundred thousand doses available by the end of the year.
https://www.marketscreener.com/ELI-LILLY-AND-COMPANY-13401/news/Eli-Lilly-and-Begins-Human-Trial-of-Antibody-Against-Covid-19-30703692/
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.